A recent survey asked HCPs how they prefer to consume medical education content. Explore their preferences and learn how to create a more effective omnichannel content strategy in
this playbook.
While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
As companies race to address global health needs, emerging vaccines and ongoing challenges underscore both the market potential and critical impact of innovation in preventive medicine. Learn more in this Trendline.
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
What is the key to an anti-obesity drug achieving sustainable weight loss? Learn how sponsors can optimize clinical trial execution to differentiate their obesity pipeline early on in this playbook.
